Pharmaceutical giant Amgen plans to invest more than $600 million in a new center for science and innovation at its global headquarters in Thousand Oaks. Construction is expected to begin in the third quarter.

The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed to drive scientific excellence and advancements in biotechnology.

“This new center will empower our scientists with the tools and collaborative environment they need to shape the next era of scientific discovery and advance medicines that improve human health,” said Robert A. Bradway, chairman and CEO at Amgen.

The announcement builds on other recent investments from the company, including a $900-million expansion of its manufacturing facility in Central Ohio and a $1-billion investment to build a second manufacturing plant in Holly Springs, NC.

From capital markets and investment strategies to development trends, leasing, and the evolving needs of healthcare providers, Connect Healthcare Real Estate 2025 dives into the most pressing issues shaping the sector, exploring how demographic shifts and economic forces are driving opportunity. Join us October 14–15, 2025, in Irvine to get ahead of what’s next in healthcare real estate:  www.ConnectHealthcareCRE2025.com